MedPageToday -- Non-small cell lung cancers and other tumors with a mutation in anaplastic lymphoma kinase (ALK) respond dramatically to a novel agent that “switches off” the faulty gene, according to early trial results.
MedPageToday -- Non-small cell lung cancers and other tumors with a mutation in anaplastic lymphoma kinase (ALK) respond dramatically to a novel agent that “switches off” the faulty gene, according to early trial results.
